DNA Electronics (DNAe)

DNAe is commercializing its pioneering semiconductor sequencing technology for healthcare applications where rapid point-of-need diagnostics are of critical need, including infectious disease and cancer testing and monitoring. It is developing the LiDia-SEQ™ system, a user-friendly, direct-from-specimen platform that performs genomic analysis on a microchip, to provide comprehensive, actionable information to clinicians in a matter of hours, versus days. DNAe’s initial focus is on infectious disease diagnostics, starting with a groundbreaking test for bloodstream infections (BSI) and antimicrobial resistance (AMR), which uses whole blood specimens to directly detect and identify infections that lead to sepsis. This will provide clinicians with actionable information to help select the appropriate antibiotics to treat the disease. A pipeline of follow-on tests is in development for viruses and cancer testing and monitoring. DNAe has received “Breakthrough Device” designation from the US Food and Drug Administration (FDA) for its pioneering platform and first assay.

Headquartered in London, UK, DNAe has expanded operations further in with a clinical diagnostic development and manufacturing site in San Diego, CA. We are always on the lookout for exceptional talent. For more details, visit www.dnae.com.

Or get in touch, we would love to hear from you. Twitter: @dna_electronics Instagram: dna.electronics